October, 2022-Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC® ODT (rimegepant), an inventive migraine treatment authorized for the acute treatment as well as the prevention of episodic migraine in adults, was acquired by Pfizer Inc., it was reported.
July 2020 - The FDA in the United States has authorized AstraZeneca's Breztri Aerosphere as a maintenance medication for patients with chronic obstructive pulmonary disease (COPD).
Breztri Aerosphere, formerly known as PT010, is an inhalation medication that contains three active ingredients: the corticosteroid budesonide, the long-acting beta-2 agonist formoterol fumarate, and the long-acting muscarinic antagonist glycopyrronium.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3164
Published Date: Jan 05, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Prevalence of laryngitis disorders, minimally invasive surgical techniques, patient-centric, and adoption of personalized medicine are some of the major growth drivers for the obstructive laryngitis treatment market.
The market size of obstructive laryngitis treatment is anticipated to attain a CAGR of 5 % over the forecast period, i.e., 2024-2036.
The major players in the market are GlaxoSmithKline plc, Reckitt Benckiser Group PLC, Sun Pharmaceutical Industries Ltd., Bayer AG, AstraZeneca, Novartis Pharmaceuticals Corporation, Walgreen Co., Prestige Consumer Healthcare Inc., Perrigo Company plc, TAIHO PHARMACEUTICAL CO., LTD. and others.
The glucocorticoid segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.